People with pneumonia who have experienced Clostridioides difficile (C. diff) infections may be able to reduce recurrences if they take doxycycline instead of the standard treatment. The study comes ...

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Researchers may not yet understand the mechanism behind recurrent Clostridium difficile infections, but they may have isolated five risk factors, according to a study published in Infection Control & ...

C. difficile, a bacterial organism, may repeatedly cause potentially fatal diarrhea upon infecting individuals with microbial dysbiosis. The conventional approach to treating CDI includes antibiotics, ...

The recent approval of the first oral fecal-derived microbiota therapy to prevent the recurrence of Clostridioides difficile (C. diff) infection in patients was welcome news for physicians who've ...

Please provide your email address to receive an email when new articles are posted on . “C. difficile is a major problem for people in the United States; it is the most common health care-associated ...

ATLANTA -- A tapered and pulsed course of vancomycin was not significantly better than a standard course of the drug for treating a first or second recurrence of Clostridioides difficile infection, a ...

Please provide your email address to receive an email when new articles are posted on . Ninety-five percent of patients achieved treatment success at 8 weeks after administration of Rebyota via ...